oncology
Medicines

Study profiles hospital admissions due to irAEs with checkpoint inhibitors

About one in ten patients treated with immune checkpoint inhibitors require hospitalisation for immune-related adverse events (irAE), a study from Queensland has found. A retrospective analysis of record for 140 patients with solid cancer treated with checkpoint inhibitors at the Royal Brisbane and Women’s Hospital and The Prince Charles Hospital in 2016 and 2017 found ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic